Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1866)	1/15/2002 7:39:51 PM
From: Biotech Jim	Read Replies (1) \| Respond to of 3202

Thanks for the article tuck, but I find it amazing that the anonymous Genome Web reporter has it wrong in stating that Dr. Friedman came most recently from Merck. In fact, he was head of research at DuPont Pharma. He intends to hire about 200 med chemists at the new Incyte. When will the company now change its name back form "genomics" to "pharma", I ask? I guess that means from Paul's perspective that we should be looking at other small molecule discovery companies with substantial cash to drive this effort <g>, obviously. Now it seems clear as to their vision. Anyone hear his presentation at H & Q care to comment? BJ